Houston sufferers are struggling to search out Ozempic as the recognition of weight reduction medication skyrockets on social media

HOUSTON – The drug Semaglutide was originally marketed under the name Ozempic for the treatment of type 2 diabetes. Last year, Semaglutide was approved by the FDA for weight loss under the Wegovy name.

Social media has given them the nickname “skinny pens” for helping people lose significant weight quickly, leading to the popularity and lack of Ozempic and Wegovy.

Drugmaker Novo Nordisk confirms it’s struggling to meet demand, and Houston patients, like Lauren Luman, say they don’t know what they’re going to do.

“I went back to my doctor and let him know that I still suffer from this deficiency. At the time, they could give me more samples, but they said, ‘We’re not sure how long we’re going to continue to have the samples available,'” Luman said.

Ozempic helped Luman lose weight and control her blood sugar. Now she says she gets the same answer at every pharmacy she visits.

“It’s been weeks or months since they had a supply,” Luman said.

Endocrinologists have said they’re frustrated that patients can’t find their medications. The endocrinologist Dr. However, Disha Narang points out that there is a need for successful weight loss drugs on the market.

“You know, our country also has an obesity epidemic, and we need to treat obesity to prevent diabetes in the first place,” said Dr. Narang.

Doctors never go wrong when prescribing Ozempic for obesity. According to the FDA, healthcare professionals can prescribe drugs off-label when medically appropriate.

“Its intended use is to be an antidiabetic,” Luman said. “So if people are just taking it for weight loss, I think maybe they should take a step back and give people who have type 2 diabetes and really need it to lower their A1C the opportunity to use this prescription.” to get.”

According to one study, weight loss can return once the patient stops taking it.

Copyright 2023 by KPRC Click2Houston – All rights reserved.

Comments are closed.